Literature DB >> 21883836

Hormone therapy for prostate cancer and the risk of stroke: a 5-year follow-up study.

Shiu-Dong Chung1, Yi-Kuang Chen, Fang-Jen Wu, Herng-Ching Lin.   

Abstract

OBJECTIVE: To examine the 5-year risk of stroke among patients with prostate cancer (PC) receiving androgen deprivation therapy (ADT) in Taiwan, using a population-based dataset. PATIENTS AND METHODS: This prospective case-control study used data sourced from the Longitudinal Health Insurance Database. The study included 365 patients with PC; 64 (17.6%) received ADT for more than 1 month. Cox proportional hazards regression was used to evaluate the association between ADT and the risk of stroke during the subsequent 5-year follow-up period, after adjusting for sociodemographic characteristics and hypertension, diabetes, coronary heart disease, heart failure, atrial fibrillation and hyperlipidaemia.
RESULTS: In the total sample of 365 patients with PC, 68 (18.6%) patients had strokes during the 5-year follow-up period. These included 11 patients with PC who received ADT (17.2% of all patients who received ADT) and 57 patients who did not receive ADT (18.9% of patients who did not receive ADT). After adjusting for potential confounders, no significant difference in the hazard of stroke was found between patients with PC who did and did not receive ADT (hazard ratio, 1.09; 95% confidence interval, 0.80-1.50).
CONCLUSION: There was no significant difference in the risk of stroke between ethnic Chinese patients with PC who did and did not receive ADT, after adjusting for potential confounders.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883836     DOI: 10.1111/j.1464-410X.2011.10459.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

Review 1.  Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective.

Authors:  Jeremy Yuen Chun Teoh; Chi-Fai Ng
Journal:  Int Urol Nephrol       Date:  2016-06-02       Impact factor: 2.370

Review 2.  Testosterone, myocardial function, and mortality.

Authors:  Vittorio Emanuele Bianchi
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 3.  Androgen receptor (AR) in cardiovascular diseases.

Authors:  Chiung-Kuei Huang; Soo Ok Lee; Eugene Chang; Haiyan Pang; Chawnshang Chang
Journal:  J Endocrinol       Date:  2016-01-14       Impact factor: 4.286

4.  No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.

Authors:  Li-Ting Kao; Herng-Ching Lin; Shiu-Dong Chung; Chao-Yuan Huang
Journal:  Asian J Androl       Date:  2017 Jul-Aug       Impact factor: 3.285

5.  Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study.

Authors:  Bum Sik Tae; Byeong Jo Jeon; Hoon Choi; Jae Hyun Bae; Jae Young Park
Journal:  Cancer Med       Date:  2019-06-10       Impact factor: 4.452

6.  Androgen Deprivation Therapy for Prostate Cancer Did Not Increase the Risk of Retinal Vascular Occlusion: A Population-Based Cohort Study.

Authors:  Hsin-Le Lin; Chia-Yi Lee; Jing-Yang Huang; Po-Chen Tseng; Shun-Fa Yang
Journal:  Int J Environ Res Public Health       Date:  2022-02-17       Impact factor: 3.390

7.  Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan.

Authors:  Kuang-Ming Liao; Yaw-Bin Huang; Chung-Yu Chen; Chen-Chun Kuo
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.